TREATMENT OF ADULT LOW AND HIGH GRADE GLIOMAS : PAST PRESENT AND FUTURE; LITERATURE REVIEWED
Abstract
Some controversy about management of gliomas has been discussed in several reports in the literatures. For low grade gliomas, conservative or aggressive treatment is considered a proper management in each case. The unpublished result of ongoing Radiation Therapy Oncology Group (RTOG) clinical trial about treatment of low grade gliomas may give some more answer in this topic. For high grade gliomas, multimodality treatment is accepted and the benefit of chemotherapy is proven at the present time. It is hoped that biotherapy will be another effective novel approach in the future for high grade gliomas.
Downloads
Metrics
References
Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathology 1993;3:255-268.
Recht LD, Lew R, Smith TW. Suspected low-grade glioma:Is deferring treatment safe? Ann Neurol 1992;31:43 1-436.
van Veelen MLC, Avezaat CJJ, Kros JM, van Putten W, Vecht CH. Supratentorial low grade astrocytoma: prognostic fators, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 1998;64:581- 587.
Feigenberg SJ, Amdur RJ, Morris CG, Mendenhall WM, Marcus RB, Friedman WA. Oligodendroglioma: Dose deferring treatment compromise outcome. Am J Clin Oncol 2003; 26: 60-66.
Dropcho EJ. Low-grade gliomas in adults. Curr Treatment Options in Neurology 2004; 6:265-271.
Karim AB, Matt B, Hatlevoll R, etal. A randomizes trial on dose-response in radiation therapy of low-grade cerebral glioma: Europeon Organization for Research and Treatment of Cancer (EORTC) Study 2284. Int J Radiat Oncol Biol Phys 1996; 36:549- 556.
Keles GE, Lamborn KR, Bergers MS. Lowgrade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001; 95:735-745.
Shaw EG, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high- dose radiation therapy in adults with supratentorial low-grade glioma: Initial report ofa North Central Cancer Treatment Group/ Radiation Therapy Oncology Group/ Eastern Cooperative Oncology Group Study. J Clin Oncol 2002;20:2267-2276.
Stupp R, Janzer RC, Hegi ME, et al. Prognostic factors for low-grade gliomas. Semin Oncol 2003;30s19:23-28.
Matz PG, Cobbs C, Berger MS. Intraoperative cortical mapping as a guide to the surgical resection of gliomas. J Neurooncol 1999; 42: 233-245.
Berman JI, Berger MS, Mukherjee P, Henry RG. Diffuse-tensor imaging-guided tracking of fibers of the pyramidal tract combined with intraoperative cortical stimulation mapping in patients with glioma. J Neurosurg 2004; 101: 66-72.
OhDS, Black PM. A low-field intraoperative MRI system for glioma surgery: is it worthwhile ? Neurosurg Clin N Am 2005; 16:135- 141.
Majos A, Tybor K, Stefanczyk L, Goraj B. Cortical mapping by functional magnetic resonance imaging in patients with brain tumors. Eur Radiol 2005; 15: 1148-1158.
Klein M, Heimans JJ, Aronson NK, et al. Effect of radiotherapy and other treatment -related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360:1361-1368.
Olson JD, Riedel E, DeAngelis LM. Long -term outcome oflow-grade oligodendroglioma and mixed glioma. Neurology 2000;54:1442-1448.
Henderson KH, Shaw EG. Randomized trial of radiation therapy in adult low-grade gliomas. Semin Radiat Oncol 2001;11:145-151.
Lo SS, Hall WA, Cho KH et al. Radiation dose response for supratentorial low-grade glioma_ institutional experience and literature review. J Neurological Sciences 2003; 214: 43-48.
Shaw EG, Daumas-Duport C, Scheithauer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989;70:853-861.
Karin ABMF, Kralendonk JH. Pitfalls and controversies in the treatment of gliomas. In: Karim ABMF, Laws ER Jr, editors. Glioma: Principles and practice in neuro-oncology. Heidelberg: Springer-Verlag; 1991.p.1-16.
Karim ABMF, Afra B, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BRO4: an interim analysis. IntJ Radiat Oncol Biol Phys 2002; 52:316-324.
Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery 1993; 32: 554-559.
Bahary JP, Villemure JG, Choi S, et al. Low -grade pure and mixed cerebral astrocytoma treated in the CT scan era. J Neurooncol 1996; 27:173-177.
Brandes AA, Vastola F, Basso U. Controversies in the therapy of low-grade glioma: When and how to treat. Expert Rev Anticancer Ther 2002;2:529-536.
Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patient with cerebral low-grade glioma. J Clin Oncol 2002;20:2076-2084.
Stieber VW. Low-grade gliomas. Curr Treat Options Oncol 2001 ;2:495-506.
Kortmann RD. Radiotherapy in low-grade gliomas: Pros. Semin Oncol 2003; 30 s19: 29-33.
Mirimanoff RO, Stupp R. Radiotherapy in low-grade glioma:Cons. Semin Oncol 2003; 30819: 34-38.
Stupp R, Baumert B. Promises and controversies in the management of low-grade glioma. Ann Oncol 2003;14:1695-1696.
Kortman RD, Jeremic B, Weller M, et al Immediate postoperative radiotherapy or "watch and wait" in the managemant of adult low-grade glioma? Strahlenther Onkol 2004; 180: 408-418.
Shaw EG, Tatter SB, Lesser GJ et al. Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol 2004;3 1:653-658.
Eyre HJ, Crowley JJ, Townsend JJ, etal. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low grade gliomas: A Southwest Oncology Group study. J Neurosurg 1993; 78: 909-914.
Mason WP, Krol GS, DeAngelis LM. Low -grade oligodendroglioma responds to chemotherapy. Neurology 1996;46:203-207.
Lesser GJ. Chemotherapy of low-grade gliomas. Semin Radiat Oncol 2001;11:138- 144.
Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003; 21: 646-651.
Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003; 14: 1722-1726.
Shaw E. RTOG 98-02: a phase II study of observation in favorable low-grade glioma and phase III stydy of radiation with or without PCV chemotherapy in unfavorable low-grade glioma. http//www.rtog.org.
Maher EA, Furnai FB, Bachoo RM, et al. Malignant glioma:genetics and biology ofa grave matter. Genes& Development 2001;15: 1311-1333.
Sanson M, Thillet J, Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol 2004; 16: 607-613.
Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study.Cancer Research 2004;64:6892-6899.
Chang S, Theodosopoulos P, Sneed P. Multidisciplinary management of adult anaplastic astrocytomas. Semin Radiat Oncol 2001; 11: 163-169.
Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin Oncol 2003; 30S 19:4-9.
Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004; 31: 635-644.
Fisher PG, Buffler PA. Malignant gliomas in 2005: Where to go from here? JAMA 2005; 293:615-617.
Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293: 557-564.
Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26: 239-244.
Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 1999; 42: 227-231.
Hentschel SJ, Sawaya R. Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control 2003;10:109-114.
Grant R, Metcalfe SE. Biopsy versus resection for malignant glioma. The Cochrane Systematic Reviews 2000, Issue 2. http://www.cochrane.org
Knauth M, Wirtz CR, Tronnier VM, et al. Intraoperative magnetic resonance tomography for control of neurosurgical operations. Radiologe. 1998; 38: 218-224.
Hirschberg H, Samset E, Hol PK, Tillung T, Lote K. Impact of intraoperative MRI on the surgical results for high-grade gliomas. Minim Invasive Neurosurg 2005;48:77-84.
Schneider JP, Trantakis C, Rubach M, et al. Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme -a quantitative radiological analysis. Neuroradiology, article in press, published online] 1 June 2005
Tatter SB. Recurrent malignant glioma in adults. Curr Treat Options Oncol 2002; 3: 509-524.
Sills AK Jr, Duntsch C, Weimar J. Therapeutic strategies for local recurrent malignant glioma. Curr Treat Options Oncol 2004;5:49 1-497.
Laperriere N, Zuraw L, Cairncross G, The Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiotherapy and Oncology 2002; 64: 259- 273.
Matsutani M. Chemoradiotherapy for brain tumors: current status and prospectives. IntJ Clin Oncol 2004; 9: 471-474.
Jansen EPM, Dewit LGH, van Herk M, Bartelink H. Target volumes in radiotherapy for high-grade malignant gliomaof the brain. Radiotherapy and Oncology 2000; 56: 151- 156.
Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998; 40: 51-55.
Brada M, Stenning SP. Radiotherapy for malignant gliomas in the elderly. Semin Oncol 2003; 30 S19: 63-67.
Shaw EG. Nothing ventured, nothing gained: treatment of glioblastoma multiforme in the elderly. J Clin Oncol 2004;9:1540-1541.
Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of radiationtherapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;9:1583-1588.
Berg G,Erik B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in brain tumours. Acta Oncol 2003;42:582-588.
Sultanem K, Patrocinio H, Lambert C, et al. The use ofhypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results ofa prospective trial. Int J Radiat Oncol Biol Phys 2004; 58:247-252.
Floyd NS, Woo SY, Teh BS, et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. IntJ Radiat Oncol Biol Phys 2004;58:72 1-726.
McGrath JJ, Tsai J-S, Engler M, et al. A phase I/II study of fractionated intensity modulated radiation therapy in the treatment of patients with primary or recurrent high grade gliomas. IntJ Radiat Oncol Biol Phys 1997; 39S 1: 269.
Gaspar LE, Zamorano LJ, Shamsa F, et al. Permanent 125 Iodine implants for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1999;43:997-982.
Lederman GS, Arbit E, Pannullo S, et al. Fractionated stereotactic radiosurgery and Taxol (FSR/T) for recurrent glioblastoma multiforme (RGBM). IntJ Radiat Oncol Biol Phys 2001351 S1:254.
Tatter SB. Recurrent glioma in adults. Curr Treat Options Oncol 2002; 3: 509-524.
Chan TA, Weingart JD, Parisi M, et al. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 2005; 64: 1133-1139.
Grosu AL, Weber WA, Franz M et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005; article in press. available online 5 May 2005.
Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002; 359: 1011-1018.
DeAngelis LM. Benefit of adjuvant chemotherapy in high-grade gliomas. Sem Oncol 2003; 30 S19:15-18.
Gilbert M,O'Neill A, Grossman S, etal. A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treated of patients with newly diagnosed glioblastoma multiforme: An Easter Cooperative Oncology Group study (E2393). J Neuro Oncol 2000;47: 145-152.
Rao RD, Krishnan S, Fitch TR, et al. Phase II trial of Carmustine, Cisplatin, and oral Etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial98-72-5 1. IntJ Radiat Oncol Biol Phys 2005;61:380-386.
Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of Temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23:2372-2377.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas:symposium review. J Neuro Oncol 2005; 73: 57-69.
Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtype of anaplastic oligodendroglioma: Implication for patient management at diagnosis. Clin Cancer Res 2001;7:839-845.
Macdonald DR. New frontiers in the treatment of malignant glioma. Semin Oncol 2003; 6 S19: 72-76.
Van Meir EG, Bellail A, Phuphanich S. Emerging molecular therapies for brain tumors. Semin Oncol 2004;31 S4:38-46.
Morokoff AP, Novak U. Targeted therapy for malignant gliomas. J Clin Neuroscience 2004, 11:807-818.
Selkirk SM. Gene therapy in clinical medicine. Postgrad. Med J 2004;80:560-570.
Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000;60: 1193-1196.
Shah AC, Benos D, Gillespie GY, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neuro Oncol 2003; 65: 203-226.
Jaganathan J, Petit JH, Lazio BE, Singh SK, Chin LS. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines. Neyrosurg Focus 2002;13:ecpl.
Puduvalli VK, Sampath D, Bruner JM, et al. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 2005; 10:233- 243.
Yu JS, Wheeler CJ, Zelter PM, et al. Vaccination of malignant glioma patients with peptide -pulsed dendrutic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842-847.
Kew Y, Levin VA. Advances in gene therapy and immunotherapy for brain tumors. Curr Opin Neurol 2003; 16:665-670.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The ASEAN Journal of Radiology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Disclosure Forms and Copyright Agreements
All authors listed on the manuscript must complete both the electronic copyright agreement. (in the case of acceptance)
